Loading...
Date of Award
Spring 2024
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Kaitlyn Gamber
Second Advisor
Alexa Arhontakis
Abstract
Diffuse Large B-cell Lymphoma is a malignant disorder of lymphocytes that appears with diffuse infiltration of lymphoid cells into lymph nodes or surrounding tissue such as the GI tract or central nervous system.1 It is the most common form of non-Hodgkin Lymphoma. Patients who are more likely to develop this lymphoma are individuals of ages 60 or older.2 .The standard first-line treatment involves combo chemotherapeutic regimen called R-CHOP. R-CHOP includes the following agents: rituximab, cyclophosphamide, doxorubicin HCl, vincristine and prednisone.
Recommended Citation
Strohl, Jacob, "Risk stratification, Treatment and Side Effect Management in Diffuse Large B Cell Lymphoma" (2024). Capstone Showcase. 86.
https://scholarworks.arcadia.edu/showcase/2024/pa/86
Risk stratification, Treatment and Side Effect Management in Diffuse Large B Cell Lymphoma
Diffuse Large B-cell Lymphoma is a malignant disorder of lymphocytes that appears with diffuse infiltration of lymphoid cells into lymph nodes or surrounding tissue such as the GI tract or central nervous system.1 It is the most common form of non-Hodgkin Lymphoma. Patients who are more likely to develop this lymphoma are individuals of ages 60 or older.2 .The standard first-line treatment involves combo chemotherapeutic regimen called R-CHOP. R-CHOP includes the following agents: rituximab, cyclophosphamide, doxorubicin HCl, vincristine and prednisone.